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Abstract  
HIV-1 infected patients who acquire HCV infection have higher rates of chronicity and liver 
disease progression than patients with HCV mono-infection.  Understanding early events in 
this pathogenic process is important.  We applied single genome sequencing of the E1 to NS3 
regions and viral pseudotype neutralization assays to explore the consequences of viral 
quasispecies evolution from pre-seroconversion to chronicity in four co-infected individuals 
(mean follow up 566 days).  We observed that one to three founder viruses were transmitted.  
Relatively low viral sequence diversity, possibly related to an impaired immune response, 
due to HIV infection was observed in three patients.  However, the fourth patient, after an 
early purifying selection displayed increasing E2 sequence evolution, possibly related to 
being on suppressive antiretroviral therapy. Viral pseudotypes generated from HCV variants 
showed relative resistance to neutralization by autologous plasma but not to plasma collected 
from later time points, confirming ongoing virus escape from antibody neutralization.  
 
Keywords: HCV quasispecies, HIV-1 co-infection, Single genome sequencing, Founder 
virus, HCV pseudotype neutralization, Antiretroviral therapy. 
 
Introduction 
   Infection with hepatitis C virus (HCV) becomes chronic in around 60-80% of patients 
(Santantonio et al., 2008).  Only about one fifth of patients are able to spontaneously clear 
infection within six months. Mechanisms by which HCV is able to evolve and avoid the host 
defense systems are now beginning to be identified (Jackowiak et al., 2014). Attention has 
focused on the envelope glycoproteins, E1 and E2, as key mediators of HCV entry. Structural 
analysis of E2 (Khan et al., 2014, Kong et al., 2013) has revealed antibody and receptor 
binding sites. Virus entry into hepatocytes occurs as a complex cascade requiring the cellular 
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factors CD81 (Zhang et al., 2004), scavenger receptor BI (SR-B1, Bartosch et al., 2003c) and 
two tight junction proteins claudin-1 (Evans et al., 2007) and occludin (Ploss et al., 2009).  
EGFR and EphA2 also contribute to entry (Lupberger et al., 2011). The two glycoproteins are 
major targets of neutralizing antibodies (Ball et al., 2014). A broadly-neutralizing antibody 
response contributes to clearance of acute infection (Dowd et al., 2008, Pestka et al., 2007, 
Raghuraman et al., 2012) and protection against reinfection (Osburn et al., 2010). 
Neutralizing activity of serum antibodies is also inversely correlated with viral titer in acute 
HCV infection (Lavillette et al., 2005). Greater understanding of virus heterogeneity and 
entry will inform the design of drug entry inhibitors and vaccines for induction of broadly 
effective immunity. 
 
   The ability of the HCV error prone RNA-dependent RNA polymerase to generate genetic 
diversity is well reported (Abe et al., 1992, Ribeiro et al., 2012, Steinhauer et al., 1992). The 
generation of many variants (quasispecies) in the presence of host-directed pressure allows 
the “most fit” species to become dominant (Bull et al., 2011).  For identification of 
genetically divergent quasispecies produced in clinical infections, single genome 
amplification (SGA, Keele et al., 2008, Simmonds et al., 1990), although labour intensive,  is 
the method of choice and has significant advantages over cloning. DNA polymerases used to 
amplify mixed populations of variants prior to cloning are able to switch templates during 
amplification and produce recombinants in vitro which do not actually exist in the original 
sample. By diluting the viral cDNA sample to a level where only a single template/variant 
molecule is present, the SGA method virtually eliminates this template switching problem. 
SGA has previously been used to examine HCV founder viruses present during the initial 
phase of infection (Li et al., 2012, Ribeiro et al., 2012, Stoddard et al., 2015). 
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   Transmission of HCV occurs in high risk groups often already burdened with other 
infections, notably HIV-1.  This has now reached epidemic significance (Arends et al., 2015, 
Fierer et al., 2008, Gambotti et al., 2005, Gilleece and Sullivan, 2005, Thomson et al., 2009, 
Turner et al., 2010, Vogel et al., 2005) and the outcome of dual infection may be 
considerably worse than HCV infection alone (Chen et al., 2014, Thomas, 2002). The factors 
that influence HCV disease progression in HIV co-infected individuals are still poorly 
defined.   
 
    We hypothesized that most of the sequence evolution would occur in the HCV E2 
envelope gene, specifically the hypervariable region 1 (HVR1, Bankwitz et al., 2010, Farci et 
al., 2000, von Hahn et al., 2007).  In addition to E2 we also investigated regions E1, p7, NS2 
and NS3 in the plasma from four HCV/HIV co-infected patients at multiple time points from 
pre-seroconversion to at least eight months, post infection. The capacity of these viruses to 
induce host antibody neutralization was assessed using the HCV pseudotype particle 
(HCVpp) expression system (Bartosch et al., 2003a, Bartosch et al., 2003b, Dowd et al., 
2009, Tarr et al., 2007, Tarr et al., 2012).  
 
Results 
Study design and patient characteristics   
   Plasma samples from four patients recently infected with HCV were studied; all were HIV-
1 infected men who have sex with men (MSM). For each patient a series of plasma samples 
was collected from pre-seroconversion through to the establishment of chronic infection. 
Three patients (B, C and M) had longstanding HIV-1 infections while one (D) had a recent 
HIV-1 seroconversion (40 days before time point 1, Tp1) and may have acquired both viruses 
as part of the same transmission event. Patient characteristics and laboratory investigations 
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including HCV seroconversion (anti-HCV), HCV RNA and genotype, ALT, CD4 T-cell 
counts, HIV-1 viral load and treatment history are summarised in Fig. 1 and Table 1. 
 
   HCV infection was acquired by sexual transmission in all patients and there was no history 
of injecting drug use or other parenteral exposure. None cleared their HCV infection 
spontaneously during follow up (at least 8 months, Fig.1). For all patients a drop in HCV 
viraemia at or around anti-HCV seroconversion coincided with a peak ALT level.  The latter 
probably reflected HCV infected cell death at around this time. A second rise in ALT (patient 
D) between Tp3 and Tp4 (Fig. 1) was investigated by re-genotyping the HCV 5’untranslated 
region (UTR) region at these time points to exclude superinfection and all UTR sequences 
were identical. Additionally, comparison of all SGA variants generated from patient D 
revealed a 92-93 % similarity to the GenBank EU234064.2 sequence confirming the 1a 
genotyping and providing no evidence of superinfection. However, it is possible that 
superinfection with the same genotype may have occurred. Chronic HBV infection with low 
level HBV viraemia was also noted in patient B. 
 
Overall HCV sequence diversity during the course of infection  
   Variant sequences from the four patients were analysed at several time points from early 
infection, between 18-42 days post the “estimated time of infection” (ETI- see below for 
definition) for Tp1, through to chronicity (follow up for 249-930 days; mean 566, Table 1). 
Only single template variants were included in the final analysis and there was no evidence of 
recombination (P <0.05) in any of the variant sequences analysed. Due to sequence 
variability in parts of the genome, several different primers were required to amplify the E1-
NS3 regions of HCV from the four patients (Table S1) and thus the precise location and 
length (bp) of the amplicons differed to some extent (Table S3, column 6). A total of 241 
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SGA-derived variants were studied with a mean of 16 (range 9-23) sequences per patient per 
time point (Table S2, column 5). Later time points showed higher numbers of mutations in 
accordance with the expected increase in genetic complexity over time, especially in variants 
analysed from patients B and D (Table S2 and highlighter plots, Fig. S1).  
 
Analysis of transmitted/founder (T/F) viruses  
   Using the Poisson-Fitter model and a mutation rate of 2.5x10-5 (Ribeiro et al., 2012) the 
viral diversity at Tp1 was analysed to examine whether the variants had a star-like (single T/F 
origin) distribution. One patient (M) revealed a non-star like pattern, patient B a near star-like 
pattern whereas two (D and C) had star-like phylogeny (Table S3). Unrooted tree analysis 
(Fig. 2) also supported the random distribution of mutations consistent with a star-like 
phylogeny for patients B, D and C. For patient M, three groups or clades of virus variants 
were discernible confirming the non-star like Poisson-Fitter result and suggesting 
transmission of three T/F viruses. Using the Poisson-Fitter model the days since the most 
recent common ancestor (MRCA) were estimated (Table S3) and approximately fitted the 
ETI for patients C, D and M (Table 1). For patient B, instead of 30 days since the estimated 
time of infection, an MRCA value of 92 days was calculated.  However, using a slightly 
higher mutation rate of 6.2x10-5, but within the reported range (Ribeiro et al., 2012), the two 
values became compatible (37 days with a range of 33-42). 
 
   Pairwise t-test analysis of genetic distance (GD) values at Tp1 (Table S2) also confirmed 
that the population diversity of the virus in patient B was significantly greater (P <0.0001) at 
the 95% level, than in patients C, D and M. The variants present in patient M were also 
significantly more diverse than those in patients C and D (P < 0.012, <0.0003, respectively).  
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Viral diversity and the appearance of a “population bottleneck” 
   For patient B high variant diversity early on in the infection led, through a purifying 
selection, to a cluster of mainly homogeneous variants (a “bottleneck”) which slowly 
diversified to give a heterogeneous collection of variants (Tp4) with three branches showing 
>70% bootstrap support (Fig. 3).  For patient D an increase in viral diversity occurred among 
the Tp4 variants (Fig. 3 and Table S2). In contrast to the phylogenetic trees derived for 
patients B and D, the trees for patients M and C failed to show evidence of positive selection 
(Fig. 3). The HCV sequences obtained at different time points from patients C and M were 
intermingled.  It is noteworthy that of the three (T/F) viruses identified in patient M, only one 
gave rise to the sequences present at Tp2 and Tp3.  
 
   Highlighter plots (Fig. S1) and Shannon Entropy data analysis (Fig. S2) illustrate 
synonymous and non-synonymous mutations, by HCV region, with the highest sequence 
complexity in the p7 (patient D, Tp4) and the E2 (patient B, Tp4) regions of the virus. All of 
the variants from patient D had different p7 region nucleotide and amino acid substitutions 
which failed to become established. The lowest entropy values were obtained from analysis 
of variants from patient C, especially in the E2 region. 
 
Amino acid changes within immune recognition and CD81 binding sites 
   To identify locations targeted by the immune response at T helper cell, B cell and CTL 
epitopes, HCV variant amino acid substitutions where selection occurred were recorded by 
HCV region (Tables 2 and 3). Single amino acid changes which were not observed at 
subsequent time points were not recorded as they were considered to have a neutral effect on 
virus fitness. 
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   Analysis of variants generated from patient B revealed the establishment of six amino acid 
mutations (V384T, A395T, A396T, I399F, G401S, P405R) within the E2 HVR1 at known T 
helper cell, B cell and CTL epitopes by the end of follow up. Three other E2 substitutions 
(outside HVR1) were present in at least 89.5% of variants by Tp4 (K408Q, 94.5%, H444Y 
89.5% and I603V, 94.7%). Only one NS2 region mutation, W841R, at a CTL epitope became 
established.  By Tp4 greater than 90% of virus variants from patient B had acquired nine non-
synonymous mutations in the E2 region.  This patients HIV RNA remained undetectable, on 
antiretroviral therapy (ART), until Tp4 (2.83 log10 copies/ml).   
 
   Substitution at amino acid residue 331 in the E1 region of variants from patient D was at a 
known T helper cell and CTL receptor recognition site (T331A, 5% at Tp1 increasing to 
100% by Tp4).  Three E2 substitutions were first seen at Tp4 (930 days post ETI) namely 
F397S, A475V, V696I. The V696I substitution (70%) which has not been previously 
reported, was identified by positive selection analysis (positive probability 0.96).  A 
substitution at position 1113, at a CTL epitope in the NS3 region, reverted from a mixed 
A1113V/T population (Tp1, Tp2, and Tp3) back to A1113 (100%, Tp4). This site was also 
identified as under positive selection by the HyPhy: FUBAR algorithm (0.98). 
 
   For patient C only a few mutations occurred in the NS3 region but none of these variants 
became established. Thus a relatively stable population of HCV variants were present and the 
immune selective pressure on the virus was probably low.  This patient was followed for only 
four months after HCV seroconversion and was treated successfully at around Tp4. 
 
9 
 
   No mutations became established in HCV variants from patient M.  Only at E837V/K in the 
NS2 region at a CTL epitope was positive selection seen (0.97 by FUBAR). The E837 
polymorphism reverted back to become the dominant variant by last time point.  For 
patient/M, variants at later time points were identified as being related to only one of the 
three T/F viruses (shown at the top of the unrooted tree for patient M, Fig. 2).  The other two 
groups of T/F viruses (bottom left and right Fig. 2) had a Q743P (E2) and/or an E837V (NS2) 
substitution (Table 2). 
 
Phenotype of the E1 and E2 proteins from majority variants  
   A single majority variant was chosen as representative of the majority sequences at each 
time point by distance matrix analysis of the E1/E2 region. This variant was cloned, re-
sequenced to confirm no errors had been introduced and expressed on the surface of retroviral 
HCVpp. Differences were observed in the HCVpp infectivity of the majority clones, with the 
sequences isolated from patient B resulting in a 10-fold greater infectivity of the Huh7 
hepatoma cells than either patient M, patient C or the positive control genotype 1a H77c 
clone (Yanagi et al., 1997, Fig. 4A).  
 
     Neutralization of each majority variant HCVpp sequence was then performed with each 
Tp plasma from the same patient (Fig.4B). For patient B, plasma (~1:1000 dilution) from Tp3 
collected at six months post seroconversion, neutralized (~50% reduction compared to  
uninhibited control preparation) the B1 HCVpp-Tp1 and B2 HCVpp-Tp2 majority variants. 
Tp4 plasma (~1:1000), collected at 20 months post seroconversion, neutralized (≥50% 
reduction compared to uninhibited control preparation) the majority variants from B1 HCV-
Tp1, B2 HCVpp-Tp2 and B3 HCV-Tp3. Thus at 1:1000 dilution the antibodies present in 
plasma Tp3 and plasma Tp4 were able to neutralize earlier HCVpp variants but not the 
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autologous majority variant. The sequence cloned from Tp4 (B4 HCVpp-Tp4) was as 
infectious as previous time points in the viral entry assay (Fig. 4A), suggesting that there was 
no significant fitness cost. Interestingly, the presence of HCV-negative control plasma 
resulted in significantly enhanced infectivity (above the uninhibited control preparation), 
most notably for the HCVpp representing Tp4 (Fig. 4B, B4 HCVpp-Tp4). This highlights the 
potential for selection of glycoproteins that have enhanced ability to infect in the presence of 
plasma during infection. 
 
   For patients C and M, only one single majority E1/E2 sequence per patient was selected by 
distance matrix analysis and persisted at each of the time points tested. In patient C, four 
months after seroconversion only the plasma from Tp4 (~1:50) was able to neutralize this 
majority sequence, C HCVpp.  Similarly, for patient M, none of the earlier time points 
demonstrated neutralization and only plasma collected 10 months after seroconversion 
(plasma Tp4; not used for SGA) was able neutralize infectivity of the M HCVpp major 
variant. In contrast to patients B, C and M, assessment of neutralization in patient D was 
prevented by the lack of functional glycoprotein clones in the HCVpp assay. Although the 
variants in patient D were cloned and sequences checked, no expression of the E1 and E2 
proteins was observed.  
 
   To test if the HCVpp expressed proteins from different patients were susceptible to 
neutralization by a well-defined broadly neutralizing antibody, we assessed the ability of 
mouse monoclonal antibody AP33 (Owsianka et al., 2005) to inhibit entry. Despite the 
observed differences in their resistance to neutralization by patient plasma, all of the HCVpp 
tested were neutralized by mAb AP33 (Fig. 4C). However, titration of the monoclonal 
antibody in these assays revealed subtle differences in the neutralization curves with the virus 
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from patient B, B4 HCVpp-Tp4 being most resistant and the virus from patient C, C HCVpp, 
being most sensitive.  
 
Discussion   
   Given the known impact of HIV infection on the natural history of HCV infection, we 
wished to explore the virus and immune system interactions following acute HCV infection 
in a group of HIV-1 infected patients.  In HCV mono-infected patients, soon after the initial 
infection, HCV diversity increases especially in the E2 HVR (Brown et al., 2005, Brown et 
al., 2012, Bull et al., 2011, Casino et al., 1999, D’Arienzo et al., 2013, Farci et al., 2000, Li et 
al., 2012 Sheridan et al., 2004, Wang et al., 2010). Initial transmission of limited numbers of 
viruses (“founders”) is followed by purifying selection by the immune response and then a 
slow emergence of variants which become established.  In HIV/HCV co-infected patients, 
Wang and colleagues (2010) reported lower diversity in the HVR1 in a cross sectional study 
using pyrosequencing.   Reduced HCV genetic complexity was also reported in HVR1 
comparing HIV-negative and co-infected patients (Lopez-Labrador et al., 2007, Shuhart et 
al., 2006). However, the impact of ART in co-infected patients has been reported to lead to 
increased quasispecies complexity (Rotman and Liang, 2009, Shuhart et al., 2006).  Gray et 
al. (2012) have proposed studying the dynamics of  the entire HCV population structure, 
including liver as well as plasma populations, in order to understand more fully the 
complexities of  HCV evolution.  
 
   In our study, soon after initial infection in two of the four patients (D, C) a set of closely 
related variants were identified.  A broader more heterogeneous mix of variants were present 
in patient B but these three patients all showed a star-like, or near star-like, grouping of 
variants (suggesting single T/F viruses) using the Poisson-Fitter model (Fig. 2, Table S3).  
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Patient M however, displayed variants derived from three T/F viruses.  The route of HCV 
infection in all patients was by sexual transmission and these findings of single or few (three) 
T/F viruses are similar to other reports (Fierer et al., 2014, Li et al., 2012).  Using t-test 
analysis of the GD at Tp1 (baseline) the variant diversity observed in patient B (Table S2), 
was significantly greater than in the other three patients and subsequently only patient B 
evolved with a narrowing of diversity or ‘bottleneck’, (Fig. 3, Table S2) where 62% of the 
virus variants were identical (Bull et al., 2011, Li et al., 2012, Ribeiro et al., 2012). In 
agreement with other investigations, our study covering the E1 to NS3 regions revealed an 
absence of insertions, deletions and recombination hot spots (Fierer et al., 2014, Shi et al., 
2012). 
 
   Spontaneous HCV clearance has been reported in co-infected patients with high CD4 and 
ALT values and low viral diversity in the E2 HVR1 region (Thomson et al., 2011). None of 
the four study patients described here experienced spontaneous HCV clearance even though 
patients C and M did display low levels of viral diversity throughout follow up.  The higher 
variant diversity which developed by Tp4 in the virus in patient B, may be associated with 
being on ART and the suppression of HIV replication (Table 1, Table S2, Bernini et al., 
2011, Shuhart et al., 2006).  This case showed similar diversity to that reported in HCV 
mono-infected patients (Brown et al., 2005, Brown et al., 2012, Bull et al., 2011, Casino et 
al., 1999, D’Arienzo et al., 2013, Farci et al., 2000, Li et al., 2012 Sheridan et al., 2004, 
Shuhart et al., 2006, Wang et al., 2010). ART may have helped to reconstitute the immune 
response to HCV, even if not sufficient to control HCV replication (Bernini et al., 2011, 
Herrero-Martinez et al., 2004). CD4 T-cell values throughout follow up were no lower than 
190 cells 106/L in all patients (Table 1) and were considered not to play a role in the observed 
differences in diversity progression however the functionality of CD4 cells was not 
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investigated. Shen and colleagues (2014) also reported that evolution was not influenced by 
CD4 levels. Lack of positive selection seen in the phylogenetic analysis of viruses from 
patients C and M may be associated with late seroconversion in (Table 1, 123 and 149 days, 
post ETI respectively) and/or the high HIV viral load at Tp1 (>5.0 log10 copies/ml). A recent 
Dutch study (Vanhommerig et al., 2014) reported a mean time to seroconversion of 74 days 
(IQR 47-125 days) in co-infected patients.  Patient D, probably co-infected with HIV and 
HCV at the same transmission event, also showed a lack of viral sequence evolution. Positive 
selection was eventually observed two and half years after the ETI, at Tp4. The HIV viral 
load was > 3.72 log10 copies/ml throughout follow up.   A second elevation in ALT (521 
IU/ml) was noted at 814 days, post ETI (Fig. 1). HCV superinfection at this time point was 
considered but no evidence of a switch in genotype or superinfection with the same genotype 
detected. 
 
      To assess the impact of the host responses on the HCV quasispecies we investigated the 
selection of amino acids variants that evolved at later time points.  Of the four patients 
studied only patient B showed sufficient immune selection pressure on amino acids in the E2 
region to drive change. These changes occurred progressively from Tp3 (270 days, post ETI) 
to Tp4 (719 days post ETI) and by the end of follow up nine non-synonymous changes in the 
E2 region (six in the HVR1) were present. These changes were at known B cell, T helper cell, 
CTL epitopes and at the CD81 binding site. Positively charged amino acids appear to 
predominate at several E2 locations, H386, R408, H488 and R648 and may modify SR-B1-
dependent entry (Koutsoudakis et al., 2012, Sabo et al., 2011). A K408Q substitution evolved 
in the virus isolated from patient B and perhaps affected SR-B1 mediated entry. Variants with 
H444Y, at a region involved in CD81 binding, also evolved and may influence HCV 
replication fitness (Deng et al., 2013a, Keck et al., 2009, Pileri et al., 1998, Tarr et al., 2012). 
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Histidine (H) is unusual at this CD81 location as tyrosine (Y) is more commonly seen and 
basic residues (K, R and H) may protect against neutralizing antibodies (Boo et al., 2012, 
Drummer et al., 2006). The positively selected substitution I603V where convergent 
evolution was detected (Table 2), is present in a ß-sheet of the core E2 domain (Kong et al., 
2013) and this site is possibly linked with modulating E1/E2 conformation and virus entry 
(Douam et al., 2014). Interesting no mutations were detected in the E2 412-424 linear epitope 
region which has been reported to be a major neutralization target (Owsianka et al., 2005, 
Tarr et al., 2015). The additional mutations in the viruses from patients C, D and M were 
dispersed mainly across regions outside of the E2 region.  The E1 T331A mutation seen in 
patient D (referred to as T139A, Douam et al., 2014) may improve virus entry and the NS3 
A1113 V/T/A fluctuation was at known CTL epitope. T cell immunity against NS3 was 
previously shown to be related to recovery from HCV infection (Deng et al., 2013b). In both 
genotype 1b infections (patients C and M) the variants showed remarkable conservation in 
the E1 and E2 regions. A limitation of this study was that no HLA typing or investigations of 
the T cell responses were carried out, which may have provided support for the CTL epitope 
evolution. 
 
   Neutralizing antibodies were observed in all patients from whom functional HCVpp were 
recovered. Limits to recovery of infectious HCVpp have been previously reported (Dowd et 
al., 2008, Flint et al., 2004, McKeating et al., 2004).  This was the case with virus in patient 
D.  For patient C, 4 months after seroconversion weakly neutralizing antibodies (plasma Tp4 
~1:50) were detected, consistent with the limited selection of variants from the virus 
population over time and a relatively weak immune response. It was 10 months before the 
antibodies (plasma Tp4) from patient M were able to neutralize the HCVpp also suggesting a 
relatively poor humoral immune response. For patient B neutralizing antibodies were present 
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at six months after seroconversion (plasma Tp3) but later samples (plasma Tp4) were more 
effective at neutralizing HCV entry. In agreement with our results, von Hahn and colleagues 
(2007) also reported neutralizing antibodies to lag behind the evolving E2 proteins in a mono-
infected patient with chronic HCV.  The HVR1 region may also influence the neutralization 
capacity of the antibodies by obstructing the CD81 binding site and preventing the antibodies 
binding to the neutralizing epitopes (Bankwitz et al., 2010). Strikingly, control HCV-negative 
human plasma caused a significant increase in infectivity in this model with the patient B 
virus at Tp4 (B4 HCVpp-Tp4, Fig. 4B). This is consistent with previous investigations that 
demonstrated enhancement of HCV entry by human serum (Lavillette et al., 2005, Bartosch 
et al., 2005).  Comparison of the phenotypes of closely-related isolates studied here revealed 
that the substitution I399F in E2 HVR1 may facilitate this enhancement, contributing to the 
SR-B1 mediated high-density lipoprotein (HDL) enhancement of infection (Bartosch et al., 
2005). This change in phenotype may protect the virus from the autologous neutralizing 
antibodies and allow it to escape. 
    
Conclusion 
   This study, even though small, provides evidence for different patterns or mechanisms of 
HCV quasispecies evolution after sexual transmission in HIV infected MSM. In all four 
patients we identified T/F viruses (one to three), but in only one patient (B) was a population 
bottleneck and subsequent E2 region evolution observed.  An improved immune response 
due to ART with the suppression of HIV replication at the time of HCV infection could have 
played a role in this instance. For the other three patients a limited increase in virus variant 
complexity emerged and notably in these cases the baseline HIV viral loads were greater than 
4 log10 copies/ml.  HCVpp neutralization studies first detected antibody neutralization at four, 
six and ten months after seroconversion and HCV variants displayed relative resistance to 
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neutralization by autologous plasma. The greatest neutralization was observed with plasma 
from later time points. We speculate that after transmission, the evolution of HCV diversity 
may be influenced by the presence of unsuppressed HIV replication which compromises the 
host immune response.  Further studies on larger patient cohorts would be required to 
confirm this speculation. 
 
 Material and methods 
Ethics statement 
   This study was conducted on stored plasma samples sent for testing at UCLH as part of 
clinical care. All patients had been enrolled in the Acute Hepatitis C Cohort at the UCL 
Centre for Sexual Health and HIV Research Unit and written informed consent was gained 
from each patient. The samples and clinical data were all anonymized. 
 
Study patients 
   Four HIV-1 infected patients (B, C, D and M) who were diagnosed with acute/recent HCV 
infection were included in the study. The HCV diagnosis was based on HCV RNA detection 
(Daniel et al., 2008) prompted by the investigation of abnormal ALT levels and confirmed by 
anti-HCV seroconversion (Architect anti-HCV assay B3C370, Abbott diagnostics, 
Wiesbaden, Germany).  Stored plasma samples available in the diagnostic laboratory were 
tested retrospectively to establish the estimated time of HCV infection (HCV ETI) as part of 
standard care. HCV ETI was taken as day zero and calculated as the midpoint between the 
last negative HCV RNA or antibody test date and the first HCV RNA positive test. Time 
point 1 (Tp1) samples were selected when HCV RNA was first detected and where there was 
a preceding HCV RNA test negative result within the previous five months.  Later time point 
selection was determined by routine clinic visits and availability of sufficient plasma (>1ml).  
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HCV RNA extraction and cDNA synthesis 
   The QIAamp Viral RNA Mini Kit (Qiagen, Manchester, UK) was used to extract RNA 
from 280 µl of plasma according to the manufacturer’s instructions. Care was taken to avoid 
vigorous vortexing to prevent shearing of long RNA templates.  The nucleic acids were 
eluted into 60 µl of 5mM Tris-HCl, pH8.0 (Tris buffer). For the cDNA step (modified from 
Fan and colleagues, 2006) 10.6 µl of RNA template was added to 9.4 µl reverse transcription 
mix consisting of 1x SuperScript® III buffer (Life technologiesTM, Invitrogen, Paisley, UK), 
0.01 M DTT, 1 µM NS3plaOA primer (Table S1), 0.5 mM dNTPs (Invitrogen), 20 units of 
RNasin ribonuclease inhibitor, 200 units of SuperScript® III RT enzyme and 5 units AMV 
RT (Promega, Southampton, UK). The reaction was performed by incubation at 50oC for 75 
min, followed by heating at 70oC for 15 min. 
 
Single genome amplification  
   cDNA was serially diluted for use as a template in the first-round of a nested PCR to find 
the dilution where less than 3/10 of PCR reactions yielded a product. A 10 µl master mix was 
prepared containing 2 µl of cDNA (or water or Tris buffer), 1x Platinum® taq high-fidelity 
buffer (Life technologies TM), 2 mM MgSO4, 0.2 mM dNTPs, 0.05 units of Platinum
® taq 
high-fidelity DNA polymerase, 5.9 µl of water and 0.2 µM of the first-round forward and 
reverse primers (Table S1). The cycling conditions were 94oC for 2 min followed by 40 
cycles of 94oC for 20 s, 60oC for 30 s, 68oC for 4 min and a final extension of 68oC for 10 
min. This was followed by a second-round PCR where 1 µl of the first round product was 
transferred to 20 µl reaction mix which contained the second-round primers (genotype 
dependent, Table S1). The 20 µl reactions were performed with a master mix of 1x Platinum® 
taq high-fidelity buffer, 2 mM MgSO4, 0.2 mM dNTPs, 0.025 units of Platinum
® taq high-
18 
 
fidelity DNA polymerase, 14.9 µl of water and 0.2 µM of each second-round forward and 
reverse primers (Table S1). The annealing temperature was changed to 64oC for the second-
round PCR. All other cycling conditions remained the same as those described for the first-
round PCR. PCR products were analysed using 1.0% agarose E-gels® (Life technologiesTM). 
SGA amplicons which were probable single templates were purified (QIAamp purification 
kit, Qiagen) prior to sequencing. Primers were designed or chosen (Table S1) to amplify the 
HCV E1 to NS3 regions from each patient. No one set of primers was able to amplify the 
virus from all four patients, thus products of between 2551-3161 bp were generated.   
Similarly, when bi-directional sequencing was performed (3130xl Genetic Analyzer machine, 
Applied Biosystems®) primers were selected (eight used per amplicon) depending on the 
patient/genotype under investigation (Table S1).  
 
Sequence analysis 
   Variant sequences were aligned using the Sequencher analysis software® 4.5 (Gene Codes 
Corporation, Ann Arbor, MI USA http://www.genecodes.com).  Any sequences containing 
mixed bases (apart from at known primer locations) were discarded and recombination 
checks using the Single Break Point analysis in the HyPhy Package were performed to check 
for evidence of recombination at the P <0.05 statistical level 
http://www.datamonkey.org/help/citations.php. Nucleotide highlighter plots analysis 
(highlighter v2.2.3 http://hcv.lanl.gov/, Keele et al., 2008) was used to visualize the evolution 
of silent (synonymous, dS) and non-silent mutations (non-synonymous, dN).  Consensus 
Maker v2.0.1 http://www.hiv.lanl.gov/  was used to determine the consensus virus sequence 
in each patient (Tp1) and this consensus sequence was used in Poisson-Fitter analysis 
http://www.hiv.lanl.gov/ (Giorgi et al., 2010) and to establish the sequence diversity and 
phylogeny.  A mutation rate of 2.5x10-5 mutations per nucleotide per genome replication 
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(Ribeiro et al., 2012) was used in the sequence analysis for Tp1 samples. Unrooted tree 
analysis using  http://www.hiv.lanl.gov/content/sequence/RAINBOWTREE (Fig. 2) at Tp1 
was performed. Phylogenetic trees (Fig. 3) for all variants generated were built using the 
program RAxML, at the nucleotide level, under the General Reversible Time (GTR) model 
of nucleotide substitution. A bootstrap analysis with 1000 replicates provided branch support. 
The genetic distances (GD) were calculated with the HyPhy package, under the GTR model 
(for nucleotide distances).  Positive selection analysis was done using three different 
algorithms from the package HyPhy: SLAC, FEL and FUBAR. Codon positions were 
considered positively selected if [dN > dS] at the P < 0.05 significance level (SLAC and 
FEL), or if the posterior probability of [dN > dS] was > 0.95. Shannon entropy values were 
determined per time point and by HCV region using a sliding window analysis 
(http://www.hiv.lanl.gov/content/sequence/ENTROPY).  HCV B cell, T-helper cell and 
cytotoxic T cell lymphocytes (CTL) epitopes were located using the HCV immunology 
database   (http://hcv.lanl.gov/content/immuno/immuno-main.html). 
 
Majority sequence selection and HCVpp studies  
   Distance matrix analysis was used to identify the majority sequences for each patient at the 
selected time points. HCVpp expression and neutralization studies were performed as 
previously described (Tarr et al., 2007). Briefly, the E1/E2 genes were amplified using the 
primers HCVppF and HCVppR (Table S1) and cloned into vector pcDNA3.1 D/V5-his-
TOPO (Life technologiesTM). HCVpp were generated in HEK 293T cells by co-transfection 
of the E1/E2 clones with a Murine Leukemia Virus packaging construct and a luciferase 
reporter plasmid (Bartosch et al 2003a). Infection assays were performed with Huh7 target 
cells in the presence of patient heat inactivated plasma and neutralization calculated as a 
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proportion of luciferase reporter expression compared with the HCV uninhibited control 
preparation. 
 
Nucleotide sequence accession numbers 
      Majority sequences used in HCVpp studies were deposited in GenBank under the 
following accession numbers……..  
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Table 1  
Patient characteristics and laboratory data. 
 
 
Patient 
ID  
 
Age   
 
HCV 
Genotype 
 
Time 
point  
(Tps) 
 
Sampling days 
at Tps since  
HCV ETI 
 
 
Estimated sero-
conversion day 
since HCV ETI 
 
 
HIV RNA  
at Tps  
(log10 copies/ml) 
 
CD4 T-cell 
count 106/L 
 
ARTa  
 
 
 
          
Bb 37 1a 1 
2 
3 
4 
 
30 
136 
270 
719 
86 Ndetc 
Ndet 
Ndet 
2.83 
290 
440 
410 
390 
 
Y 
Y 
Y 
N 
 
Dd 31 1a 1 
2 
3 
4 
 
 
29 
113 
181 
930 
29 4.17 
3.72 
4.23 
5.34 
400 
290 
580 
490 
 
N 
N 
N 
N 
 
Ce 24 1b 1 
2 
3 
4 
18 
66 
151 
249 
123 5.23 
4.70 
Ndet 
Ndet 
280 
350 
390 
530 
 
N 
N 
Y 
Y 
 
M 48 1b 1 
2 
3 
42 
149 
366 
149 5.59 
Ndet 
Ndet 
190 
390 
300 
N 
Y 
Y 
 
 
 
a Y indicates treatment with antiretroviral treatment (ART) and N indicates no treatment. 
b HBV co-infection (3.0 log10 IU/ml) at time point 1. 
c Ndet indicates not detected and this was where virus levels were below the level of 
detection (1.7 HIV log10 copies/ml). 
d Recent anti-HIV seroconversion. 
e 24 weeks of HCV treatment started on day 249 since HCV ETI with pegylated interferon α 
and ribavirin. 
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Table 2 
Evolution of amino acid substitutions in HCV variants analysed from patients B, D, C and M. Single non-synonymous mutations where amino 
acids failed to establish at subsequent time points are not shown. 
   
 
Patient ID 
and Tp 
 
Days since 
HCV ETI 
 
 
E1 
192-383 
 
E2 
384-746 
 
NS2 
810-1026 
 
NS3 
1027-1223 
   Mutation Variants with 
Mutation 
% of variants 
with 
mutation 
Mutation Variants with 
Mutation 
% of variants 
with 
mutation 
Mutation Variants with 
mutation 
% of variants 
with 
mutation 
 
B Tp1 
 
 
 
30 
 
Tp 1 
dominant 
sequence 
identified 
 
 
V384T 
I603V 
E717D 
 
1/23 
4/23 
4/23 
 
4.3 
17.4 
17.4 
 
      
 
 
B Tp2 
 
136 
 
No change 
 
V384T 
G401D 
21/21 
1/21 
100 
4.8 
W841R 21/21 
 
100 
 
   
B  Tp3 
 
 
270 No change 
 
 
V384T 
G401S 
P405Q 
K408Q 
K408M 
H444Y 
A563V 
 
29/29 
1/29 
1/29 
13/29 
7/29 
1/29 
3/29 
100 
3.4 
3.4 
44.8 
24.1 
2.4 
10.3 
W841R 
L864 
frame 
shift 
 
29/29 
1/29 
100 
3.4 
R1187G 1/29 3.4 
B Tp4 
 
 
719 No change 
 
V384T 
A395T 
A396T 
I399F 
G401S 
P405R 
K408Q 
H444Y 
N446K 
I603V 
 
19/19 
19/19 
19/19 
19/19 
19/19 
19/19 
18/19 
17/19 
2/19 
18/19 
100 
100 
100 
100 
100 
100 
94.7 
89.5 
10.5 
94.7 
W841R 
L864 
frame 
shift 
V895I 
19/19 
1/19 
 
 
9/19 
100 
5.3 
 
 
47.3 
R1187G 1/19 5.3 
 
Underlined mutation at I603V undergoes convergent evolution with P >0.001 using SLAC and FEL algorithms [dN>dS] where P <0.05 values 
are significant. 
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Patient ID 
and Tp 
 
Days since 
HCV ETI 
 
E1 
192-383 
 
E2 
384-746 
 
 
NS2 
810-1026 
 
 NS3 
1027-1223 
  Mutation Variants 
with 
mutation 
% of 
variants 
with 
mutation 
Mutation Variants 
with 
mutation 
% of 
variants 
with 
mutation 
Mutation Variants 
with 
mutation 
% of  
variants  
with 
mutation 
Mutation Variants with 
mutation 
% of 
variants 
with 
mutation 
 
D Tp1 
 
 
29 
 
T331A 
 
1/20 
 
5 
       
A1113V 
A1113T 
 
1/20 
1/20 
 
5 
5 
D Tp2 
 
 
113 T331A 10/18 55.5    T812A 1/18 5.5 A1113V 
A1113T 
8/18 
1/18 
44.4 
5.5 
D Tp3 
 
 
181 T331A 10/11 90.9       A1113V 
A1113T 
9/11 
1/11 
81.8 
9.1 
D Tp4 
 
 
930 T331A 10/10 100 F397S 
A475V 
V696I 
10/10 
7/10 
7/10 
100 
70 
70 
T812A 
A929V 
4/10 
7/10 
40 
70 
ALL  NOW 
A1113 
10/10 100 
 
Underlined mutations at V696I and A1113V/T undergo convergent evolution with a posterior probability 0.96 and 0.98 respectively using 
FUBAR algorithm of [dN>dS] >0.95. 
 
 
 
 
Patient ID 
and Tp 
 
Days since 
HCV ETI 
 
 NS3 
1027-1223 
                            Mutation Variants with 
mutation 
% of 
variants 
with 
mutation 
 
C Tp1 
 
 
18 
 
 
 
 
 
 
C Tp2 66    
C Tp3 151 A1113S 4/10 40 
 
C Tp4 249 A1113S 
 
1/10 
 
10 
36 
 
 
 
Patient ID 
and Tp 
 
Days since 
HCV ETI 
 
E2 
384-746 
 
 
NS2 
810-1026 
  Mutation Variants 
with 
mutation 
% of 
variants 
with 
mutation 
Mutation Variants 
with 
Mutation 
% of variants 
with 
mutation 
 
M Tp1 
 
 
42 
 
Q743P 
 
 
5/20 
 
25 
 
E837V 
 
10/20 
 
 
50 
 
 
M Tp2 149    E837K 
G1017D 
 
1/11 
1/11 
 
9.1 
9.1 
 
M Tp3 
 
 
366    E837K 
I1010V 
G1017D 
1/9 
4/9 
3/9 
11.1 
44.4 
33.3 
        
 
Underlined mutation at E837V/K undergoes convergent evolution  
-posterior probability 0.97 using FUBAR algorithm of [dN>dS] >0.95.
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Table 3  
HCV epitope locations and CD81 binding sites where amino acids evolved.  
 
 
Patient 
ID 
 
Possible 
B cell epitope 
location 
(neutralizing) 
 
 
Possible 
CTL epitope 
location 
 
Possible 
T helper cell  
location 
 
 
CD81a             
binding  
sites 
 
 
 
B 
 
384 E2 HVR1 
395 E2 HVR1 
396b E2 HVR1  
399b E2 HVR1  
401b E2 HVR1  
405b E2 HVR1  
408 E2 
444 E2 
446 E2 
 
 
 
395 E2 
396 E2 
399 E2 
401 E2 
405 E2 
408 E2 
717 E2 
841 NS2 
1187 NS3 
 
395 E2 
396 E2 
399 E2 
401 E2 
405 E2 
408 E2 
1187 NS3 
 
 
 
444 E2            
446 E2 
 
 
 
 
 
 
 
D 397b E2 HVR1 
475 E2 HVR2 
 
331 E1  
475 E2 
1113 NS3  
 
331 E1 
397 E2 
 
 
C  1113 NS3 
 
  
M  837 NS2 
1010 NS2 
1017 NS2 
 
743 E2 
1010 NS2 
1017 NS2 
 
 
a Reference, Pileri et al., 1998. 
b SR-B1 binding site location. 
HCV B cell, T helper cell and cytotoxic T cell (CTL) epitopes were located using the HCV 
immunology database http://hcv.lanl.gov/content/immuno/immuno-main.html. 
1 
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Figure captions                                                                                                         
Fig. 1. Laboratory parameters at the time points (Tps) studied. The solid lines show HCV 
RNA  values in IU/ml and the Tps at which SGA was performed are labelled.   ALT values 
(IU/L) are indicated by dashed lines. The normal range of ALT is 10-50 IU/L. The arrows 
define the time of anti-HCV seroconversion and the open triangle (patient C, Tp4) indicates 
start of successful treatment. HCV ETI to Tp1 for patient B was 30 days, patient D 29 days, 
patient C 18 days and patient M 42 days.  
 
Fig. 2. Unrooted phylogenetic tree analysis of SGA-derived sequences at Tp1 using  
http://www.hiv.lanl.gov/content/sequence/RAINBOWTREE. Sequences from patients B, C 
and D clustered around a central node indicating that the productive HCV infection was due 
to a single virus whereas M displayed three separate groups/lineages suggesting infection 
with three different founder viruses.  
 
Fig. 3. Phylogenetic trees of patient derived SGA E1-NS3 sequences.  Variants at the 
different time points are colour coded (Tp1- yellow, Tp2- green, Tp3- red and Tp4 -blue). 
The trees where rooted against a sequence from another patient and the branches represent 
nucleotide substitutions per site. A bootstrap analysis, with 1000 replicates, was done to 
assess branch support. Branches with a support > 70% are labelled with a star (*). 
 
Fig. 4. HCVpp infectivity results where all reactions were performed in triplicate.  (A) 
HCVpp infectivity levels displayed by the expression of the majority E1/E2 sequences from 
patients C, (C HCVpp), M, (M HCVpp) and B1 (B1 HCVpp-Tp1), B2 (B2 HCVpp-Tp2), B3 
(B3 HCVpp-Tp3), B4 (B4 HCVpp-Tp4) in relation to controls H77c and VSV-G (measured 
in relative light units, RLU). (B) Each graph represents the infectivity of the HCV 
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pseudoparticles (HCVpp) derived from patient B, C and M in the presence of patient plasma (     
plasma Tp1,     plasma Tp2,      plasma Tp3,     plasma Tp4) compared to the signal achieved 
with an uninhibited control preparation of each HCVpp. Each HCVpp represents the majority 
E1/E2 amino acid sequence sampled at each time point (B1 HCVpp-Tp1, B2 HCVpp-Tp2,  
B3 HCVpp-Tp3,  B4 HCVpp-Tp4, C HCVpp, M HCVpp). An HCV-negative control plasma 
was also included  (    ). Greatest neutralization was seen with the later time point plasma 
samples.  (C) Neutralization of the HCVpp expressed E1/E2 proteins, selected from three 
patients (from left to right, B1, 2, 3, 4 HCVpp; C HCVpp; M HCVpp) by the broadly reactive 
AP33 monoclonal antibody.  Data are expressed as a proportion of the signal observed with 
the uninhibited HCVpp. Serial dilution of the AP33 antibody revealed varying degrees of 
neutralization; B4 HCVpp derived from patient B at Tp4 being the most resistant to 
neutralization and that from patient C HCVpp the least resistant.  
